Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children (CAVASTHME)

17. juni 2016 opdateret af: University Hospital, Toulouse

Asthma affects about 10% of children and 6% of adults in industrialized countries. Lymphocytes (L) Th2, a T cell population (LT) producing interleukin (IL) -4, 5 and 13 are broadly involved in this pathology in experimental models and in humans. Many studies show that the signaling pathways activated by the commitment of T receiver differ depending LT. The identification of specific signaling pathways links to Th2 offer new therapeutic approaches. Precedent study showed that mouse Th2 selectively expressed related to calcium channels sensitive channels Cav1 voltage, normally found in excitable cells where they are defined as receivers dihydropyridine (DHP).

The goal of the present study is to show the presence of Cav1 channels in inflammatory cells in allergic asthmatics and show overexpression of these channels in the peripheral blood mononuclear cells from asthmatic subjects before and / or after stimulation with the TCR in comparison with controls.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

60

Fase

  • Ikke anvendelig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år til 18 år (Barn, Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

For Asthmatic children arm :

  • Girl not in childbearing potential or taking contraceptive treatment
  • Asthma diagnosis in at least 6 months as defined by clinical symptoms (expiratory dyspnea, wheezing, sibilance) and respiratory function (reversibility of VEMS at least 12% after salbutamol administration)
  • Allergologic tests positives to airborne allergens : positive prick test and/or specific IgE > 0,35 kU/L for at least one allergen
  • Asthma severity between mild to moderate based on Global initiative for asthma classification during more than one month with inhaled corticotherapies +/- long term action beta -mimetic long compounds (salmeterol, formoterol)
  • Patient insured with a social security scheme

For control children arm :

  • Girl not in childbearing potential or taking contraceptive treatment
  • No medical history of asthma
  • No medical history of allergy or symptoms of allergy on skin (atopic dermatitis), respiratory tract (rhino-conjunctivitis, asthma) or food allergy

Exclusion Criteria:

For both arms:

  • Chronic respiratory pathology : known occlusive or restrictive respiratory syndrome like interstitial lung disease, neuromuscular disease, mucoviscidoses, respiratory tract abnormalities with cough, dyspnea or digital hippocratism.
  • History of pulmonary or nose and throat infectious disease during last 4 months
  • Parasitic disease non treated during last 3 months
  • Dyspnea during the inclusion
  • Systemic corticotherapy during the last 3 months before inclusion
  • Immunosuppressive therapy during the last 3 months before inclusion
  • Diabeta
  • Disease causing immune disorder
  • Infection during inclusion
  • Participation to another study witch implies medical treatment during last 3 months before inclusion

For asthmatic children arm :

  • Chronic pulmonary pathology (excluding asthma)
  • Asthma exacerbation during inclusion
  • VEMS < 70% of normal range or VEMS < 70% of normal range after inhalation of serum (despite salbutamol administration)
  • Patient unable to complete pulmonary function testing

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Asthmatic children
Induced sputum method using hypertonic serum
Collection of expectoration in sterile vial, conserved in ice all along the examination
Sham-komparator: Control children
Induced sputum method using hypertonic serum
Collection of expectoration in sterile vial, conserved in ice all along the examination

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Detection of sequence coding for Cav1 in cells as assessed by reverse transcription polymerase chain reaction
Tidsramme: Day 1
Day 1

Sekundære resultatmål

Resultatmål
Tidsramme
Presence of Cav1 channels as assessed by correlation between Cav1 expression and eosinophils in expectoration collection
Tidsramme: Day 1
Day 1
Presence of Cav1 channels as assessed by correlation between Cav1 expression and lymphocytes T in expectoration collection
Tidsramme: Day 1
Day 1
Comparison of CRTH2+ cells in total blood between asthmatic and control group
Tidsramme: Day 1
Day 1
Comparison of Cav1 channels and cytokines Th2 expression between asthmatic and control group before T-Cell receptor stimulation
Tidsramme: Day 1
Day 1
Comparison of Cav1 channels and cytokines Th2 expression between asthmatic and control group after T-Cell receptor stimulation
Tidsramme: Day 1
Day 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: François Brémont, MD, Hôpital des Enfants CHU Toulouse

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2013

Primær færdiggørelse (Faktiske)

1. maj 2016

Studieafslutning (Faktiske)

1. maj 2016

Datoer for studieregistrering

Først indsendt

17. maj 2016

Først indsendt, der opfyldte QC-kriterier

17. juni 2016

Først opslået (Skøn)

22. juni 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

22. juni 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. juni 2016

Sidst verificeret

1. juni 2016

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner